Anticardiolipin and anti-β2-glycoprotein I antibodies in Behcet's disease

Journal of Korean Medical Science

Volumn 13, Issue 4, 1998, Pages 400-404

  Kang, Hee Jung ^a   Lee, Yun Woo ^b   Han, Seong Hoon ^b   Cho, Hyun Chan ^a   Lee, Kyu Man ^a  

^a Hallym University   (South Korea)

^b Inje University   (South Korea)

Author keywords

Antibodies, anticardiolipin; Behcet's syndrome

Indexed keywords

ANTIBODY; BETA2 GLYCOPROTEIN 1; CARDIOLIPIN ANTIBODY; GLYCOPROTEIN;

ADULT; ARTICLE; BEHCET DISEASE; BLOOD; FEMALE; HUMAN; IMMUNOLOGY; MALE; MIDDLE AGED;

ADULT; ANTIBODIES; ANTIBODIES, ANTICARDIOLIPIN; BEHCET SYNDROME; BETA 2-GLYCOPROTEIN I; FEMALE; GLYCOPROTEINS; HUMANS; MALE; MIDDLE AGED;

EID: 0032129949     PISSN: 10118934     EISSN: None     Source Type: Journal    
DOI: 10.3346/jkms.1998.13.4.400     Document Type: Article

References (30)

1. 2 glycoprotein I clearly differentiates anticardiolipin antibodies from antiphospholipid syndrome and syphilis. Thromb Haemost 1996; 75: 717-20.
2. 2-glycoprotem-I assay for discrimination between anticardiolipin antibodies associated with infection and increased risk of thrombosis. Br J Haematol 1995; 91: 471-3.
3. 2-glycoprotein I is bound to a suitable surface. Thromb Haemost 1995; 73: 29-34.
4. Horkko S, Miller E, Dudl E, Reaven P, Curtiss LK, Zvaifler NJ, et al. Antiphospholipid antibodies are directed against epitopes of oxidized phospholipids. Recognition of cardiolipin by monoclonal antibodies to epitopes of oxidized low density lipoprotein. J Clin Invest 1996; 98: 815-25.
5. Koike T, Tsutsumi A, Ichikawa K, Matsuura E. Antigenic specificity of the "anticardiolipin" antibodies. Blood 1995; 85: 2277-80.
6. International Study Group for Behcet's Disease. Criteria for diagnosis of Behcet's disease. Lancet 1990; 335: 1078-80.
7. Lee ES, Lee YD, Bang D, Lee SH, Lee S. A study of interleukin 2 activity in Behcet's syndrome. Ann Dermatol 1991; 5: 5-11.
8. Harris EN, Gharavi AE, Patel SP, Hughes GRV. Evaluation of the anticardiolipin test: report of an international workshop held 4 April 1986. Clin Exp Immunol 1987; 68: 215-22.
9. Finazzi G, Brancaccio V, Moia M, Ciaverella N, Mazzucconi MG, Schinco PC, Ruggeri M, Pogliani EM, Gamba G, Rossi E, Baudo F, Manotti C, D'Angelo A, Palareti G, De Stefano V, Berrettini M, Barbui T. Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a four-year prospective study from the Italian Registry. Am J Med 1996; 100: 530-6.
10. 2-glycoprotein I: preparation, properties and availability to investigator. Clin Chem 1996; 42: 1-2.
11. McNeil HP, Chesterman CN, Krilis SA. Immunology and clinical importance of aniphospholipid antibodies. Adv Immunol 1991; 49: 193-280.
12. 2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci USA 1990; 87: 4120-4.
13. 2 glycoprotein I is potentiated by a distinct subgroup of anticardiolipin antibodies. Thromb Haemost 1992; 68: 297-300.
14. 2-glycoprotein I. Thromb Haemost 1992; 67: 499-502.
15. 2-glycoprotein I. J Clin Invest 1992; 90: 1100-4.
16. Galli M, Comfurius P, Maassen C, Hemker HC, de Baets MH, van Breda-Vriesman PJ, Barbui T, Zwaal RF, Bevers EM. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 1990; 335: 1544-7.
17. 2-GPI) enhances cardiolipin binding activity but is not the antigen for phospholipid antibodies. Br J Haematol 1992; 82: 565-70.
18. 2-glycoprotein I antigenicity induced by phospholipid binding. Thromb Haemost 1993; 69: 361-5.
19. 2-glycoprotein I as an antigen. J Immunol Methods 1991; 143: 223-9.
20. Chamley LW, McKay EJ, Pattison NS. Cofactor dependent and cofactor independent anticardiolipin antibodies. Thromb Res 1991; 61: 291-9.
21. 2-glycoprotein I. Thromb Haemost 1993; 69: 1011.
22. Matsuura E, Igarashi Y, Fujimoto M, Ichikawa K, Koike T. Heterogeneity of anticardiolipin antibodies defined by the anticardiolipin cofactor. J Immunol 1992; 148: 3885-91.
23. Hull RG, Harris EN, Gharavi AE, Tincani A, Asherson RA, Valesini G, Denman AM, Froude G, Hughes GR. Anticardiolipin antibodies: occurrence in Behcet's syndrome. Ann Rheum Dis 1984; 43: 746-8.
24. Zouboulis CC, Puttner P, Tebbe B, Orfanos CE. Anticardiolipin antibodies in Admantiades-Behcet's disease. Br J Dermatol 1993; 128: 281-4.
25. Ji HG, Bang DS, Lee SN, Cha YS. Anticardiolipin antibodies in patients with Behcet's disease. Ann Dermatol 1991; 32: 326-9.
26. Park DJ, Hong OJ, Kim SH, Park SY, Kim HY, Kim DJ. Anticardiolipin antibody measured by ELISA in Behcet's disease. Korean J Int Med 1989; 37: 205-9.
27. Silver RM, Porter TF, van Leeuween I, Jeng G, Scott JR, Branch DW. Anticardiolipin antibodies: clinical consequences of "low liters". Obstet Gynecol 1996; 87: 494-500.
28. Bang DS, Ji HG, Choi YS, Lee SN. Absence of lupus anticoagulants in Behcet's disease. Yonsei Med J 1991; 32: 326-9.
29. Pengo V, Biasiolo A, Brocco T, Tonetto S, Ruffatti A. Auto-antibodies to phospholipid-binding plasma proteins in patients with thrombosis and phospholipid-reactive antibodies. Thromb Haemost 1996; 75: 721-4.
30. 2-glycoprotein I, antithrombin antibodies, and lupus anticoagulant in patients with systemic lupus erythematosus with a history of thrombosis. J Rheumatol 1997; 24: 1710-5.